Drug intelligence / Profile preview

CKD-846

Development stage: Phase 1
Lead developer: Chong Kun Dang Pharmaceutical
Modality: Small Molecules
Administration: Parenteral

Overview

CKD-846 is an incrementally modified drug (IMD) under development by Chong Kun Dang Pharmaceutical for the treatment of benign prostatic hyperplasia (BPH). It is a small molecule drug administered via the parenteral route. As of early 2024, it is in Phase 1 clinical trials for BPH. The specific mechanism of action has not been disclosed publicly, but it targets urogenital diseases, specifically prostatic hyperplasia[1][2][4].

Beyond the preview

Go deeper on CKD-846.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CKD-846.

Explore the full profile